Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Clinical trial NCT04768881 · TERMINATED
Trial details
- NCT number
- NCT04768881
- Sponsor
- Karyopharm Therapeutics Inc
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-12
- Primary completion
- 2023-09-22
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.